A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt

Department of Medicine, University of Western Ontario, London, Canada.

OBJECTIVES. A double-blind randomized trial was designed to determine the efficacy of intravenous and oral disopyramide phosphate in preventing neurally mediated syncope induced by a head-up tilt test. BACKGROUND. Neurally mediated syncope is a frequent cause of syncope and may be induced by head-up tilt testing. Recent uncontrolled trials have suggested that disopyramide may be an effective therapy in patients with neurally mediated syncope. METHODS. Twenty-two consecutive patients with recurrent neurally mediated syncope and two or more successive positive head-up tilt test responses were randomly allocated to receive either intravenous disopyramide or placebo. Head-up tilt testing at 60 degrees was performed for 15 min. If presyncope or syncope was not provoked, isoproterenol infusion was started at a rate of 1 microgram/min and the rate gradually increased until a 25% increase in heart rate was achieved. Eleven patients were subsequently randomized in crossover fashion to receive oral disopyramide (800 mg/day) or placebo during 1 week. The primary end point was prevention of syncope or presyncope provoked by head-up tilt testing. RESULTS. Head-up tilt test results were positive for syncope in 12 (75%) of 16 patients receiving intravenous placebo and in 12 (60%) of 20 patients receiving disopyramide (p = 0.55 Fisher exact test, 95% confidence interval [CI] -14% to 40%). In the intravenous phase, complete crossover was achieved in 15 patients. Head-up tilt test results during this phase were positive in 13 patients (87%) receiving placebo and in 12 patients (80%) receiving disopyramide (p = 0.50 Fisher exact test, 95% CI -19% to 32%) and were positive in all patients receiving their initially randomized drug or placebo. In the oral phase, head-up tilt results were positive in only two patients (18%) assigned to placebo and in three patients (27%) receiving disopyramide (p = 0.54 Fisher exact test, 95% CI -42% to 24%). A mean follow-up time of 29 +/- 8 months was obtained in 21 of the 22 patients. Syncope recurred in 3 (27%) of the 11 patients receiving disopyramide and 3 (30%) of the 10 patients not treated pharmacologically (p > 0.05). CONCLUSIONS. Intravenous disopyramide was ineffective for the prevention of neurally mediated syncope provoked by head-up tilt testing. No significant effect was observed after oral therapy with disopyramide. There was a striking decrease in the incidence of positive tilt test results over time regardless of intervention, thus discouraging the use of head-up tilt as the single method of assessing therapeutic efficacy. Recurrence of syncope after the investigative protocol was infrequent over long-term follow-up regardless of treatment group.

This article has been cited by other articles:

				S. Petkar and A. Fitzpatrick Tilt-table testing: transient loss of consciousness discriminator or epiphenomenon? Europace, June 1, 2008; 10(6): 747 - 750. [Full Text] [PDF]

				M. P. Tan and S. W. Parry Vasovagal syncope in the older patient. J. Am. Coll. Cardiol., February 12, 2008; 51(6): 599 - 606. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, P. E. Vardas, A. Auricchio, J.-J. Blanc, J.-C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F. B. Morgado, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association Europace, October 1, 2007; 9(10): 959 - 998. [Full Text] [PDF]

				Authors/Task Force Members, P. E. Vardas, A. Auricchio, J.-J. Blanc, J.-C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F. B. Morgado, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association Eur. Heart J., September 2, 2007; 28(18): 2256 - 2295. [Full Text] [PDF]

				H. Ector, R. Willems, H. Heidbüchel, and T. Reybrouck Repeated tilt testing in patients with tilt-positive neurally mediated syncope Europace, January 1, 2005; 7(6): 628 - 633. [Abstract] [Full Text] [PDF]

				A. Raviele, F. Giada, C. Menozzi, G. Speca, S. Orazi, G. Gasparini, R. Sutton, M. Brignole, and for the Vasovagal Syncope and Pacing Trial Investi A randomized, double-blind, placebo-controlled study of permanent cardiac pacing for the treatment of recurrent tilt-induced vasovagal syncope. The vasovagal syncope and pacing trial (SYNPACE) Eur. Heart J., October 1, 2004; 25(19): 1741 - 1748. [Abstract] [Full Text] [PDF]

				G. Foglia-Manzillo, F. Giada, G. Gaggioli, A. Bartoletti, G. Lolli, M. Dinelli, A. Del Rosso, M. Santarone, A. Raviele, and M. Brignole Efficacy of tilt training in the treatment of neurally mediated syncope. A randomized study Europace, January 1, 2004; 6(3): 199 - 204. [Abstract] [Full Text] [PDF]

				Guidelines on Management (diagnosis and treatment) of syncope - update 2004: The Task Force on Syncope, European Society of Cardiology Europace, January 1, 2004; 6(6): 467 - 537. [Full Text] [PDF]

				J. Sagrista-Sauleda, B. Romero, G. Permanyer-Miralda, A. Moya, and J. Soler-Soler Reproducibility of sequential head-up tilt testing in patients with recent syncope, normal ECG and no structural heart disease Eur. Heart J., November 1, 2002; 23(21): 1706 - 1713. [Abstract] [Full Text] [PDF]

				P. Flevari, E. G. Livanis, G. N. Theodorakis, E. Zarvalis, T. Mesiskli, and D. T. h Kremastinos Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients' well-being J. Am. Coll. Cardiol., August 7, 2002; 40(3): 499 - 504. [Abstract] [Full Text] [PDF]

				Task Force on Syncope, European Society of Cardiol, M Brignole, P Alboni, D Benditt, L Bergfeldt, J.J Blanc, P.E Bloch Thomsen, J.G van Dijk, A Fitzpatrick, S Hohnloser, et al. Guidelines on management (diagnosis and treatment) of syncope Eur. Heart J., August 1, 2001; 22(15): 1256 - 1306. [Abstract] [PDF]

				A. H. Madrid, J. Ortega, J. G. Rebollo, J. G. Manzano, J. G. Segovia, A. Sanchez, G. Pena, and C. Moro Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo-controlled study J. Am. Coll. Cardiol., February 1, 2001; 37(2): 554 - 559. [Abstract] [Full Text] [PDF]

				M. Lamarre-Cliche and J. Cusson The fainting patient: value of the head-upright tilt-table test in adult patients with orthostatic intolerance Can. Med. Assoc. J., February 1, 2001; 164(3): 372 - 376. [Abstract] [Full Text] [PDF]

				A. Raviele, F. Giada, R. Sutton, P. Alboni, M. Brignole, A. Del Rosso, E. di Girolamo, R. Luise, and C. Menozzi The Vasovagal Syncope and Pacing (Synpace) trial: rationale and study design Europace, January 1, 2001; 3(4): 336 - 341. [Abstract] [PDF]

				A. M. Fenton, S. C. Hammill, R. F. Rea, P. A. Low, and W.-K. Shen Vasovagal Syncope Ann Intern Med, November 7, 2000; 133(9): 714 - 725. [Abstract] [Full Text] [PDF]

				M. Brignole, C. Menozzi, A. Del Rosso, S. Costa, G. Gaggioli, N. Bottoni, P. Bartoli, and R. Sutton New classification of haemodynamics of vasovagal syncope: beyond the VASIS classification: Analysis of the pre-syncopal phase of the tilt test without and with nitroglycerin challenge Europace, January 1, 2000; 2(1): 66 - 76. [Abstract] [PDF]

				H. Ector Neurocardiogenic, vasovagal syncope Eur. Heart J., December 1, 1999; 20(23): 1686 - 1687. [PDF]

				M Santini, F Ammirati, F Colivicchi, G Gentilucci, and V Guido The effect of atropine in vasovagal syncope induced by head-up tilt testing Eur. Heart J., December 1, 1999; 20(23): 1745 - 1751. [Abstract] [PDF]

				S.W. Parry and R.A. Kenny The management of vasovagal syncope QJM, December 1, 1999; 92(12): 697 - 705. [Full Text] [PDF]

				E. Di Girolamo, C. Di Iorio, L. Leonzio, P. Sabatini, and A. Barsotti Usefulness of a Tilt Training Program for the Prevention of Refractory Neurocardiogenic Syncope in Adolescents : A Controlled Study Circulation, October 26, 1999; 100(17): 1798 - 1801. [Abstract] [Full Text] [PDF]

				D. G. Benditt, G. J. Fahy, K. G. Lurie, S. Sakaguchi, W. Fabian, and N. Samniah Pharmacotherapy of Neurally Mediated Syncope Circulation, September 14, 1999; 100(11): 1242 - 1248. [Abstract] [Full Text] [PDF]

				A. Raviele, M. Brignole, R. Sutton, P. Alboni, P. Giani, C. Menozzi, and A. Moya Effect of Etilefrine in Preventing Syncopal Recurrence in Patients With Vasovagal Syncope : A Double-Blind, Randomized, Placebo-Controlled Trial Circulation, March 23, 1999; 99(11): 1452 - 1457. [Abstract] [Full Text] [PDF]

				D. Flammang, M. Antiel, T. Church, A. Chassing, D. Hamani, E. Donal, and M. Waynberger Is a pacemaker indicated for vasovagal patients with severe cardioinhibitory reflex as identified by the ATP test?: A preliminary randomized trial Europace, January 1, 1999; 1(2): 140 - 145. [Abstract] [PDF]

				C R Ward, J C Gray, J J Gilroy, and R A Kenny Midodrine: a role in the management of neurocardiogenic syncope Heart, January 1, 1998; 79(1): 45 - 49. [Abstract] [Full Text] [PDF]

				A. Englund, M. Fredrikson, and M.°r. Rosenqvist Head-up Tilt Test: A Nonspecific Method of Evaluating Patients With Bifascicular Block Circulation, February 18, 1997; 95(4): 951 - 954. [Abstract] [Full Text]

				G. J. Klein, B. J. Gersh, and R. Yee Electrophysiological Testing : The Final Court of Appeal for Diagnosis of Syncope? Circulation, September 1, 1995; 92(5): 1332 - 1335. [Full Text]